Abstract 2601
Background
Immune checkpoint inhibitors (ICIs) acting against CTLA-4 and PD-1 represent a strenght therapy in patients (pts) with metastatic melanoma (MM). Antineoplastic activity of ICIs through the activation of immune cells in tumor lesions raised challenge in evaluation of treatment response by imaging. Aim of this study was to compare diagnostic accuracy of different 18F-FDG PET/CT parameters (Metabolic Tumor Volume, MTV; Total Lesion Glycolisis, TLG; Maximum Standardised Uptake Value, SUVmax) to predict therapy response and clinical outcome in pts with MM treated with Ipilimumab (Ipi) and Nivolumab (Nivo) or Pembrolizumab (Pem) and to check for accuracy differences specific for the class of treatment.
Methods
57 MM pts receiving Ipi (25) or PD-1 inhibitors (Nivo 19; Pem 13) who performed a 18F-FDG PET/CT scan at the beginning (PET0) and after completion of Ipi or during anti PD-1 (PET1), were retrospectively evaluated. Response at PET1 was classified as PD, SD, PR and CR according to RECIST 1.1, EORTC criteria and by percentage change of MTV and TLG (cut off values: +43% for PD and -43% for PR, calculated by ROC analysis) of up to 5 target lesions. PET Response Evaluation Criteria for Immunotherapy (PERCIMT) were assessed alone and with the previously described parameters. Performance of each criteria at PET1 to predict pts having clinical benefit (CR, PR and SD) and no clinical benefit (PD) at 6 months since starting ICIs were assessed and correlated to time-to-progression.
Results
For Ipi pts group, best predictors of response were: variation of MTV (Sensitivity 1; Specificity 0.84; accuracy 0.96) and TLG (Se 0.89; Sp; 93.8; acc 0.92), with PERCIMT criteria for progressive disease. In anti-PD1 group overlapping predictivity values were found for EORTC, MTV and TLG (Se 0.95; Sp 1; Acc 0.97). Reliability of above parameters was also confirmed in predicting pts progression free survival at 12 and 24 months.
Conclusions
18F-FDG PET/CT performed 3 months later the first administration could predict response to ICIs and long-term patient clinical outcome. Performance of 18F-FDG PET/CT parameters and criteria in predicting response to ICIs is influenced by the class of treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Local Ethic committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract